Monday, November 25, 2013
For more than a quarter century, I have been negotiating and living with contracts involving all types of sponsors, from the world’s largest pharmaceutical companies to biotechnology startups and entrepreneurs working out of their homes. Risk sharing in these relationships is currently a popular topic in blogs, trade magazines and conferences that serve our industry. This paper is a contribution which I hope many will find helpful. I have found that equitable risk sharing can lead to the kind of long term relationship that benefits both parties. My perspective is that of a leading CRO/CMO which provides niche, high value manufacturing for clinical trials and low volume commercial products, as well as premium drug lead development services. In my experience, the most satisfactory contracts are those which bind the parties in a “joined at the hip” relationship.
Download full white paper to learn more. Download full white paper to learn more.